From Nasdaq: 2024-05-19 08:59:17

Novavax (NASDAQ: NVAX) stock is currently trading at $13 per share, a significant decrease from its peak of $320 in February 2021. Despite a recent surge of nearly 200% due to a licensing deal with Sanofi worth $1.2 billion, the stock has underperformed the S&P 500 in 2022 and 2023.

During the 2020-2023 timeline, Novavax stock faced a consistent decline, losing 90% of its value from $110 to $13, while the S&P 500 showed a 40% increase. However, the High Quality Portfolio, with 30 stocks, outperformed the S&P 500 each year. Analysts estimate an over 35% upside for NVAX stock.

Amid the ongoing inflation shock, NVAX stock faces uncertainty, but potential for gains once market sentiments improve. Novavax’s fundamentals show revenue growth from $22 million in 2020 to $1.6 billion in 2022, falling to $556 million in 2023. The recent Sanofi deal will strengthen its financial position.

Looking back at the 2007-08 crisis, NVAX stock declined 78% from $73 to $16 but showed a strong recovery to $53. Its revenue increased from $22 million to $1.6 billion with a net loss of $4.40 per share in 2023. Novavax’s cash flow situation improved after the Sanofi deal.



Read more at Nasdaq: Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?